GeoVax director granted 6,000 stock options
GeoVax Labs, Inc. director Robert T. McNally received a grant of stock options covering 6,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
GeoVax Labs, Inc. director Robert T. McNally received a grant of stock options covering 6,000 shares of common stock. The options have a $1.18 per-share exercise price, become exercisable on June 17, 2027, and expire on June 17, 2036. Following this compensation-related award, his directly held derivative position from this grant totals 6,000 options, and the filing shows no open-market buying or selling activity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 6,000 | $0.00 | $0.00 |
Key Figures
Key Terms
Stock Option financial
Common Stock financial
Grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did GeoVax (GOVX) disclose in this Form 4?
How many GeoVax (GOVX) stock options were granted to Robert T. McNally?
What is the exercise price and term of the new GeoVax (GOVX) options?
Does this GeoVax (GOVX) Form 4 show any open-market buying or selling?
How did the GeoVax (GOVX) option grant change McNally’s reported holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.